Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$13.81 USD
+0.56 (4.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $13.80 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TEVA 13.81 +0.56(4.23%)
Will TEVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Other News for TEVA
June 7th Options Now Available For Teva Pharmaceutical Industries
AbbVie stock slides 6% amid concerns about falling Humira sales
The Sound Shore Fund Q1 2024 Letter To Shareholders
US Supreme Court reportedly declines to hear Vanda patent case
Vanda Pharmaceuticals responds to U.S. Supreme Court denial of petition